KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $413.5 million.

  • Acadia Pharmaceuticals' Total Liabilities rose 345.54% to $413.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $413.5 million, marking a year-over-year increase of 345.54%. This contributed to the annual value of $455.0 million for FY2024, which is 4343.05% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Total Liabilities of $413.5 million as of Q3 2025, which was up 345.54% from $403.2 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Total Liabilities' 5-year high stood at $455.0 million during Q4 2024, with a 5-year trough of $150.7 million in Q3 2021.
  • Moreover, its 5-year median value for Total Liabilities was $270.4 million (2023), whereas its average is $279.3 million.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Total Liabilities surged by 6926.5% in 2023, and later crashed by 611.98% in 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Total Liabilities (Quarter) stood at $159.2 million in 2021, then grew by 17.69% to $187.4 million in 2022, then surged by 69.27% to $317.2 million in 2023, then soared by 43.43% to $455.0 million in 2024, then decreased by 9.11% to $413.5 million in 2025.
  • Its Total Liabilities stands at $413.5 million for Q3 2025, versus $403.2 million for Q2 2025 and $367.1 million for Q1 2025.